ANSI Advanced Neuromodulation Systems (MM)

ANS' Newest Lead, Lamitrode Tripole 8, Allows Precision in Pain Treatment Unique Design Provides Greater Accuracy and Control to Enhance the Performance of ANS Spinal Cord Stimulators PLANO, Texas, Nov. 22 /PRNewswire-FirstCall/ -- Advanced Neuromodulation Systems, Inc. (NASDAQ:ANSI) (ANS) today introduced the Lamitrode(R) Tripole 8 lead, a significant addition to its growing family of leads. The first of its kind on the market, this innovative surgical lead features a three-column electrode array, which allows clinicians to direct the stimulation current more precisely to nerve structures deep in the spinal cord. "We designed the Tripole 8 to facilitate precise delivery of stimulation to the low back area," said Claudio A. Feler, M.D. and designer of the new lead. "The resulting improved coverage is intended to help physicians enhance therapy for their patients." The six independently controlled midline contacts and optional anodal guards (lateral contacts used as a single anode) give the Tripole 8 lead a tremendous amount of programming flexibility. The tripolar configuration is designed to allow the electrical field to be steered longitudinally along the lead and laterally across the lead array when used in conjunction with the ANS propriety MultiStim(R) technology. This "steerability" helps to confine the stimulation field between electrodes, making it possible for clinicians to more effectively target the back fibers that cause pain and to provide a broader area of stimulation coverage. "The Lamitrode(R) Tripole 8 lead is another example of our cooperative efforts with renowned physicians to develop cutting-edge neurostimulation technology -- a top priority for ANS, as we strive to create superior products that address significant clinical needs," said ANS President and CEO Chris Chavez. About chronic pain Chronic pain affects an estimated 50 million Americans, of whom more than half are partially or totally disabled. At present, approximately $100 billion are spent in the U.S. on the diagnosis and treatment of chronic pain, which represents the most common indication for spinal cord stimulation therapy. The 106th U.S. Congress has declared this the "Decade of Pain Control and Research," helping to bring spinal cord stimulation to the forefront as a viable and effective option in the treatment of chronic pain. About Advanced Neuromodulation Systems (ANS) Advanced Neuromodulation Systems, Inc. designs, develops, manufactures and markets implantable systems used to manage chronic intractable pain and other disorders of the central nervous system. A technology leader in the neuromodulation industry, ANS offers a family of proprietary neurostimulation devices and implantable drug pumps for an expanding range of therapeutic applications. ANS was recently named among FORTUNE's 100 Fastest Growing Companies and has been recognized among Forbes' 200 Best Small Companies for two consecutive years. Frost & Sullivan also recently honored the company with its Product Innovation Award. Additional information is available at http://www.ans-medical.com/ . DATASOURCE: Advanced Neuromodulation Systems, Inc. CONTACT: Stephanie Coggin, +1-972-716-0500 x 17, or , for Advanced Neuromodulation Systems, Inc. Web site: http://www.ans-medical.com/

Copyright